CompletedPhase 1NCT00383994

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Issa F. Khouri, MD, PA-C
M.D. Anderson Cancer Center
Intervention
GM-CSF(drug)
Enrollment
6 enrolled
Eligibility
All sexes
Timeline
20062019

Study locations (1)

Collaborators

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00383994 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials